somatomedin

So, levels of somatomedin and growth hormone are controlled via negative feedback.

Several structures has been reported for the Somatomedin B domain.

When somatomedin levels are high, they reduce growth hormone levels by stimulating somatostatin production.

He wondered if the huge animals had been treated with Gene, Inc.'s, Somatomedin.

The Somatomedin B domain is a close-knit disulfide knot, with 4 disulfide bonds within 35 residues.

As Jason flipped through it, he realized that it detailed the creation of the recombinant strain of bacteria to produce Somatomedin.

A somatomedin receptor is a receptor which binds somatomedin.

The somatomedin B domain of vitronectin binds to plasminogen activator inhibitor-1 (PAI-1), and stabilizes it.

The symptoms include decreased growth hormone (GH) and somatomedin secretion, very short stature, weight that is inappropriate for the height, and immature skeletal age.

The Somatomedin B domain interacts with the urokinase receptor, and this interaction has been implicated in cell migration and signal transduction.

He did have the protocol for producing the Somatomedin E. coli strain, but that hardly seemed a major discovery, and all the other lab book outlined was failure.

Insulin-like growth factor 1 (IGF-1), also called somatomedin C, is a protein that in humans is encoded by the IGF1 gene.

Somatomedin B is a serum factor of unknown function, is a small cysteine-rich peptide, derived proteolytically from the N-terminus of the cell-substrate adhesion protein vitronectin.

The cDNA encodes a protein of 1,404 amino acids (human A isoform) with a somatomedin B homology domain, heparin-binding domains, multiple mucin-like repeats, a hemopexin domain, and an aggregation domain.

Cys-rich somatomedin B-like domains are found in a number of proteins, including plasma-cell membrane glycoprotein (which has nucleotide pyrophosphate and alkaline phosphodiesterase I activities) and placental protein 11 (which appears to possess amidolytic activity).

Associated abnormalities vary and may include facial dysmorphism, upslanting palpebral fissures, hypertelorism, cleft palate, genital anomalies, mild developmental delay, ureterocele, smooth muscle hamartoma, nevus lipomatosus, Laron syndrome (dwarfism with high growth hormone and low somatomedin activity), and other defects.

The SMB domain of vitronectin has been demonstrated to interact with both the urokinase receptor and the plasminogen activator inhibitor-1 (PAI-1) and the conserved cysteines of the NPP1 somatomedin B-like domain have been shown to mediate homodimerization.